APO Research
Talk to an analyst

APO RESEARCH · REPORT

GABAA Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

GABAA Receptor Agonists Industry Research Report 2026

20 December 2025148 pages

Choose your research edition.

Industry ResearchGABAA Receptor Agonists Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal GABAA Receptor Agonists Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal GABAA Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GABAA Receptor Agonists Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal GABAA Receptor Agonists Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global GABAA Receptor Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for GABAA Receptor Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for GABAA Receptor Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of GABAA Receptor Agonists include Takeda, Teva, Sun Pharma, Shanghai Pharmaceuticals Holding, Sandoz, Sanofi, Novartis, Mylan and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global GABAA Receptor Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

GABAA Receptor Agonists Market by Company

Takeda

Teva

Sun Pharma

Shanghai Pharmaceuticals Holding

Sandoz

Sanofi

Novartis

Mylan

Roche

Pfizer

Huazhong Pharmaceutical

Sichuan HaiscoPharmaceuical

GSK

Fresenius Kabi

Changzhou Siyao Pharmaceutical

AstraZeneca

WG Critical Care

Viatris

Torrent Pharma

SAGE Therapeutics

Neurelis

Hikma

CHEPLAPHARM

Apotex

Akorn

GABAA Receptor Agonists Segment by Type

BZDs

Non-BZDs

GABAA Receptor Agonists Segment by Application

Epilepsy

Anxiety

Neuropathic Pain

Insomnia

Other

GABAA Receptor Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAA Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GABAA Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAA Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of GABAA Receptor Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of GABAA Receptor Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of GABAA Receptor Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global GABAA Receptor Agonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global GABAA Receptor Agonists Sales (k units) of Manufacturers (2021-2026) Table 7. Global GABAA Receptor Agonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global GABAA Receptor Agonists Revenue of Manufacturers (2021-2026) Table 9. Global GABAA Receptor Agonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market GABAA Receptor Agonists Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global GABAA Receptor Agonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of GABAA Receptor Agonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of GABAA Receptor Agonists, Product Type & Application Table 14. Global GABAA Receptor Agonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global GABAA Receptor Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Takeda GABAA Receptor Agonists Product Portfolio Table 22. Takeda Recent Developments Table 23. Teva Company Information Table 24. Teva Business Overview Table 25. Teva GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Teva GABAA Receptor Agonists Product Portfolio Table 27. Teva Recent Developments Table 28. Sun Pharma Company Information Table 29. Sun Pharma Business Overview Table 30. Sun Pharma GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sun Pharma GABAA Receptor Agonists Product Portfolio Table 32. Sun Pharma Recent Developments Table 33. Shanghai Pharmaceuticals Holding Company Information Table 34. Shanghai Pharmaceuticals Holding Business Overview Table 35. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio Table 37. Shanghai Pharmaceuticals Holding Recent Developments Table 38. Sandoz Company Information Table 39. Sandoz Business Overview Table 40. Sandoz GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Sandoz GABAA Receptor Agonists Product Portfolio Table 42. Sandoz Recent Developments Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Sanofi GABAA Receptor Agonists Product Portfolio Table 47. Sanofi Recent Developments Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Novartis GABAA Receptor Agonists Product Portfolio Table 52. Novartis Recent Developments Table 53. Mylan Company Information Table 54. Mylan Business Overview Table 55. Mylan GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Mylan GABAA Receptor Agonists Product Portfolio Table 57. Mylan Recent Developments Table 58. Roche Company Information Table 59. Roche Business Overview Table 60. Roche GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Roche GABAA Receptor Agonists Product Portfolio Table 62. Roche Recent Developments Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Pfizer GABAA Receptor Agonists Product Portfolio Table 67. Pfizer Recent Developments Table 68. Huazhong Pharmaceutical Company Information Table 69. Huazhong Pharmaceutical Business Overview Table 70. Huazhong Pharmaceutical GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 72. Huazhong Pharmaceutical Recent Developments Table 73. Sichuan HaiscoPharmaceuical Company Information Table 74. Sichuan HaiscoPharmaceuical Business Overview Table 75. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio Table 77. Sichuan HaiscoPharmaceuical Recent Developments Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. GSK GABAA Receptor Agonists Product Portfolio Table 82. GSK Recent Developments Table 83. Fresenius Kabi Company Information Table 84. Fresenius Kabi Business Overview Table 85. Fresenius Kabi GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Fresenius Kabi GABAA Receptor Agonists Product Portfolio Table 87. Fresenius Kabi Recent Developments Table 88. Changzhou Siyao Pharmaceutical Company Information Table 89. Changzhou Siyao Pharmaceutical Business Overview Table 90. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 92. Changzhou Siyao Pharmaceutical Recent Developments Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. AstraZeneca GABAA Receptor Agonists Product Portfolio Table 97. AstraZeneca Recent Developments Table 98. WG Critical Care Company Information Table 99. WG Critical Care Business Overview Table 100. WG Critical Care GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. WG Critical Care GABAA Receptor Agonists Product Portfolio Table 102. WG Critical Care Recent Developments Table 103. Viatris Company Information Table 104. Viatris Business Overview Table 105. Viatris GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Viatris GABAA Receptor Agonists Product Portfolio Table 107. Viatris Recent Developments Table 108. Torrent Pharma Company Information Table 109. Torrent Pharma Business Overview Table 110. Torrent Pharma GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Torrent Pharma GABAA Receptor Agonists Product Portfolio Table 112. Torrent Pharma Recent Developments Table 113. SAGE Therapeutics Company Information Table 114. SAGE Therapeutics Business Overview Table 115. SAGE Therapeutics GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. SAGE Therapeutics GABAA Receptor Agonists Product Portfolio Table 117. SAGE Therapeutics Recent Developments Table 118. Neurelis Company Information Table 119. Neurelis Business Overview Table 120. Neurelis GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Neurelis GABAA Receptor Agonists Product Portfolio Table 122. Neurelis Recent Developments Table 123. Hikma Company Information Table 124. Hikma Business Overview Table 125. Hikma GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Hikma GABAA Receptor Agonists Product Portfolio Table 127. Hikma Recent Developments Table 128. CHEPLAPHARM Company Information Table 129. CHEPLAPHARM Business Overview Table 130. CHEPLAPHARM GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. CHEPLAPHARM GABAA Receptor Agonists Product Portfolio Table 132. CHEPLAPHARM Recent Developments Table 133. Apotex Company Information Table 134. Apotex Business Overview Table 135. Apotex GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Apotex GABAA Receptor Agonists Product Portfolio Table 137. Apotex Recent Developments Table 138. Akorn Company Information Table 139. Akorn Business Overview Table 140. Akorn GABAA Receptor Agonists Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Akorn GABAA Receptor Agonists Product Portfolio Table 142. Akorn Recent Developments Table 143. Global GABAA Receptor Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 144. Global GABAA Receptor Agonists Sales by Region (2021-2026) & (k units) Table 145. Global GABAA Receptor Agonists Sales Market Share by Region (2021-2026) Table 146. Global GABAA Receptor Agonists Sales by Region (2027-2032) & (k units) Table 147. Global GABAA Receptor Agonists Sales Market Share by Region (2027-2032) Table 148. Global GABAA Receptor Agonists Revenue by Region (2021-2026) & (US$ Million) Table 149. Global GABAA Receptor Agonists Revenue Market Share by Region (2021-2026) Table 150. Global GABAA Receptor Agonists Revenue by Region (2027-2032) & (US$ Million) Table 151. Global GABAA Receptor Agonists Revenue Market Share by Region (2027-2032) Table 152. North America GABAA Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. North America GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 154. North America GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 155. North America GABAA Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 156. North America GABAA Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 157. Europe GABAA Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Europe GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 159. Europe GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 160. Europe GABAA Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 161. Europe GABAA Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 162. Asia Pacific GABAA Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Asia Pacific GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 164. Asia Pacific GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 165. Asia Pacific GABAA Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 166. Asia Pacific GABAA Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 167. South America GABAA Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. South America GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 169. South America GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 170. South America GABAA Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 171. South America GABAA Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa GABAA Receptor Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. Middle East and Africa GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 174. Middle East and Africa GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 175. Middle East and Africa GABAA Receptor Agonists Revenue by Country (2021-2026) & (US$ Million) Table 176. Middle East and Africa GABAA Receptor Agonists Revenue by Country (2027-2032) & (US$ Million) Table 177. Global GABAA Receptor Agonists Sales by Type (2021-2026) & (k units) Table 178. Global GABAA Receptor Agonists Sales by Type (2027-2032) & (k units) Table 179. Global GABAA Receptor Agonists Sales Market Share by Type (2021-2026) Table 180. Global GABAA Receptor Agonists Sales Market Share by Type (2027-2032) Table 181. Global GABAA Receptor Agonists Revenue by Type (2021-2026) & (US$ Million) Table 182. Global GABAA Receptor Agonists Revenue by Type (2027-2032) & (US$ Million) Table 183. Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2026) Table 184. Global GABAA Receptor Agonists Revenue Market Share by Type (2027-2032) Table 185. Global GABAA Receptor Agonists Price by Type (2021-2026) & (US$/unit) Table 186. Global GABAA Receptor Agonists Price by Type (2027-2032) & (US$/unit) Table 187. Global GABAA Receptor Agonists Sales by Application (2021-2026) & (k units) Table 188. Global GABAA Receptor Agonists Sales by Application (2027-2032) & (k units) Table 189. Global GABAA Receptor Agonists Sales Market Share by Application (2021-2026) Table 190. Global GABAA Receptor Agonists Sales Market Share by Application (2027-2032) Table 191. Global GABAA Receptor Agonists Revenue by Application (2021-2026) & (US$ Million) Table 192. Global GABAA Receptor Agonists Revenue by Application (2027-2032) & (US$ Million) Table 193. Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2026) Table 194. Global GABAA Receptor Agonists Revenue Market Share by Application (2027-2032) Table 195. Global GABAA Receptor Agonists Price by Application (2021-2026) & (US$/unit) Table 196. Global GABAA Receptor Agonists Price by Application (2027-2032) & (US$/unit) Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. GABAA Receptor Agonists Distributors List Table 200. GABAA Receptor Agonists Customers List Table 201. GABAA Receptor Agonists Industry Trends Table 202. GABAA Receptor Agonists Industry Drivers Table 203. GABAA Receptor Agonists Industry Restraints Table 204. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. GABAA Receptor Agonists Product Image Figure 5. Global GABAA Receptor Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global GABAA Receptor Agonists Market Size (2021-2032) & (US$ Million) Figure 7. Global GABAA Receptor Agonists Sales (2021-2032) & (k units) Figure 8. Global GABAA Receptor Agonists Average Price (US$/unit) & (2021-2032) Figure 9. BZDs Product Image Figure 10. Non-BZDs Product Image Figure 11. Epilepsy Product Image Figure 12. Anxiety Product Image Figure 13. Neuropathic Pain Product Image Figure 14. Insomnia Product Image Figure 15. Other Product Image Figure 16. Global GABAA Receptor Agonists Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of GABAA Receptor Agonists, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 GABAA Receptor Agonists Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global GABAA Receptor Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global GABAA Receptor Agonists Sales by Region in 2025 Figure 22. Global GABAA Receptor Agonists Revenue by Region in 2025 Figure 23. North America GABAA Receptor Agonists Market Size by Country in 2025 Figure 24. North America GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 25. North America GABAA Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 26. United States GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe GABAA Receptor Agonists Market Size by Country in 2025 Figure 30. Europe GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 31. Europe GABAA Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 32. Germany GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific GABAA Receptor Agonists Market Size by Country in 2025 Figure 43. Asia Pacific GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific GABAA Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 45. China GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America GABAA Receptor Agonists Market Size by Country in 2025 Figure 54. South America GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 55. South America GABAA Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 56. Brazil GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa GABAA Receptor Agonists Market Size by Country in 2025 Figure 60. Middle East and Africa GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa GABAA Receptor Agonists Revenue Market Share by Country (2021-2032) Figure 62. Egypt GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries GABAA Receptor Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global GABAA Receptor Agonists Sales Market Share by Type (2021-2032) Figure 68. Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2032) Figure 69. Global GABAA Receptor Agonists Price (US$/unit) by Type (2021-2032) Figure 70. Global GABAA Receptor Agonists Sales Market Share by Application (2021-2032) Figure 71. Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2032) Figure 72. Global GABAA Receptor Agonists Price (US$/unit) by Application (2021-2032) Figure 73. GABAA Receptor Agonists Value Chain Figure 74. GABAA Receptor Agonists Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. GABAA Receptor Agonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • BZDs
  • Non-BZDs
Applications
  • Epilepsy
  • Anxiety
  • Neuropathic Pain
  • Insomnia
  • Other
Companies covered
  • Takeda
  • Teva
  • Sun Pharma
  • Shanghai Pharmaceuticals Holding
  • Sandoz
  • Sanofi
  • Novartis
  • Mylan
  • Roche
  • Pfizer
  • Huazhong Pharmaceutical
  • Sichuan HaiscoPharmaceuical
  • GSK
  • Fresenius Kabi
  • Changzhou Siyao Pharmaceutical
  • AstraZeneca
  • WG Critical Care
  • Viatris
  • Torrent Pharma
  • SAGE Therapeutics
  • Neurelis
  • Hikma
  • CHEPLAPHARM
  • Apotex
  • Akorn

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global GABAA Receptor Agonists Market Size (2021-2032)
  4. 2.2.2 Global GABAA Receptor Agonists Sales (2021-2032)
  5. 2.2.3 Global GABAA Receptor Agonists Market Average Price (2021-2032)
  6. 2.3 GABAA Receptor Agonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 BZDs
  9. 2.3.3 Non-BZDs
  10. 2.4 GABAA Receptor Agonists by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Epilepsy
  13. 2.4.3 Anxiety
  14. 2.4.4 Neuropathic Pain
  15. 2.4.5 Insomnia
  16. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global GABAA Receptor Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global GABAA Receptor Agonists Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global GABAA Receptor Agonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global GABAA Receptor Agonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global GABAA Receptor Agonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of GABAA Receptor Agonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of GABAA Receptor Agonists, Product Type & Application
  8. 3.8 Global Manufacturers of GABAA Receptor Agonists, Established Date
  9. 3.9 Global GABAA Receptor Agonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda GABAA Receptor Agonists Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Teva
  8. 4.2.1 Teva Company Information
  9. 4.2.2 Teva Business Overview
  10. 4.2.3 Teva GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva GABAA Receptor Agonists Product Portfolio
  12. 4.2.5 Teva Recent Developments
  13. 4.3 Sun Pharma
  14. 4.3.1 Sun Pharma Company Information
  15. 4.3.2 Sun Pharma Business Overview
  16. 4.3.3 Sun Pharma GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sun Pharma GABAA Receptor Agonists Product Portfolio
  18. 4.3.5 Sun Pharma Recent Developments
  19. 4.4 Shanghai Pharmaceuticals Holding
  20. 4.4.1 Shanghai Pharmaceuticals Holding Company Information
  21. 4.4.2 Shanghai Pharmaceuticals Holding Business Overview
  22. 4.4.3 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio
  24. 4.4.5 Shanghai Pharmaceuticals Holding Recent Developments
  25. 4.5 Sandoz
  26. 4.5.1 Sandoz Company Information
  27. 4.5.2 Sandoz Business Overview
  28. 4.5.3 Sandoz GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sandoz GABAA Receptor Agonists Product Portfolio
  30. 4.5.5 Sandoz Recent Developments
  31. 4.6 Sanofi
  32. 4.6.1 Sanofi Company Information
  33. 4.6.2 Sanofi Business Overview
  34. 4.6.3 Sanofi GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sanofi GABAA Receptor Agonists Product Portfolio
  36. 4.6.5 Sanofi Recent Developments
  37. 4.7 Novartis
  38. 4.7.1 Novartis Company Information
  39. 4.7.2 Novartis Business Overview
  40. 4.7.3 Novartis GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Novartis GABAA Receptor Agonists Product Portfolio
  42. 4.7.5 Novartis Recent Developments
  43. 4.8 Mylan
  44. 4.8.1 Mylan Company Information
  45. 4.8.2 Mylan Business Overview
  46. 4.8.3 Mylan GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Mylan GABAA Receptor Agonists Product Portfolio
  48. 4.8.5 Mylan Recent Developments
  49. 4.9 Roche
  50. 4.9.1 Roche Company Information
  51. 4.9.2 Roche Business Overview
  52. 4.9.3 Roche GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Roche GABAA Receptor Agonists Product Portfolio
  54. 4.9.5 Roche Recent Developments
  55. 4.10 Pfizer
  56. 4.10.1 Pfizer Company Information
  57. 4.10.2 Pfizer Business Overview
  58. 4.10.3 Pfizer GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Pfizer GABAA Receptor Agonists Product Portfolio
  60. 4.10.5 Pfizer Recent Developments
  61. 4.11 Huazhong Pharmaceutical
  62. 4.11.1 Huazhong Pharmaceutical Company Information
  63. 4.11.2 Huazhong Pharmaceutical Business Overview
  64. 4.11.3 Huazhong Pharmaceutical GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio
  66. 4.11.5 Huazhong Pharmaceutical Recent Developments
  67. 4.12 Sichuan HaiscoPharmaceuical
  68. 4.12.1 Sichuan HaiscoPharmaceuical Company Information
  69. 4.12.2 Sichuan HaiscoPharmaceuical Business Overview
  70. 4.12.3 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio
  72. 4.12.5 Sichuan HaiscoPharmaceuical Recent Developments
  73. 4.13 GSK
  74. 4.13.1 GSK Company Information
  75. 4.13.2 GSK Business Overview
  76. 4.13.3 GSK GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 GSK GABAA Receptor Agonists Product Portfolio
  78. 4.13.5 GSK Recent Developments
  79. 4.14 Fresenius Kabi
  80. 4.14.1 Fresenius Kabi Company Information
  81. 4.14.2 Fresenius Kabi Business Overview
  82. 4.14.3 Fresenius Kabi GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Fresenius Kabi GABAA Receptor Agonists Product Portfolio
  84. 4.14.5 Fresenius Kabi Recent Developments
  85. 4.15 Changzhou Siyao Pharmaceutical
  86. 4.15.1 Changzhou Siyao Pharmaceutical Company Information
  87. 4.15.2 Changzhou Siyao Pharmaceutical Business Overview
  88. 4.15.3 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio
  90. 4.15.5 Changzhou Siyao Pharmaceutical Recent Developments
  91. 4.16 AstraZeneca
  92. 4.16.1 AstraZeneca Company Information
  93. 4.16.2 AstraZeneca Business Overview
  94. 4.16.3 AstraZeneca GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 AstraZeneca GABAA Receptor Agonists Product Portfolio
  96. 4.16.5 AstraZeneca Recent Developments
  97. 4.17 WG Critical Care
  98. 4.17.1 WG Critical Care Company Information
  99. 4.17.2 WG Critical Care Business Overview
  100. 4.17.3 WG Critical Care GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 WG Critical Care GABAA Receptor Agonists Product Portfolio
  102. 4.17.5 WG Critical Care Recent Developments
  103. 4.18 Viatris
  104. 4.18.1 Viatris Company Information
  105. 4.18.2 Viatris Business Overview
  106. 4.18.3 Viatris GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Viatris GABAA Receptor Agonists Product Portfolio
  108. 4.18.5 Viatris Recent Developments
  109. 4.19 Torrent Pharma
  110. 4.19.1 Torrent Pharma Company Information
  111. 4.19.2 Torrent Pharma Business Overview
  112. 4.19.3 Torrent Pharma GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Torrent Pharma GABAA Receptor Agonists Product Portfolio
  114. 4.19.5 Torrent Pharma Recent Developments
  115. 4.20 SAGE Therapeutics
  116. 4.20.1 SAGE Therapeutics Company Information
  117. 4.20.2 SAGE Therapeutics Business Overview
  118. 4.20.3 SAGE Therapeutics GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 SAGE Therapeutics GABAA Receptor Agonists Product Portfolio
  120. 4.20.5 SAGE Therapeutics Recent Developments
  121. 4.21 Neurelis
  122. 4.21.1 Neurelis Company Information
  123. 4.21.2 Neurelis Business Overview
  124. 4.21.3 Neurelis GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Neurelis GABAA Receptor Agonists Product Portfolio
  126. 4.21.5 Neurelis Recent Developments
  127. 4.22 Hikma
  128. 4.22.1 Hikma Company Information
  129. 4.22.2 Hikma Business Overview
  130. 4.22.3 Hikma GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Hikma GABAA Receptor Agonists Product Portfolio
  132. 4.22.5 Hikma Recent Developments
  133. 4.23 CHEPLAPHARM
  134. 4.23.1 CHEPLAPHARM Company Information
  135. 4.23.2 CHEPLAPHARM Business Overview
  136. 4.23.3 CHEPLAPHARM GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 CHEPLAPHARM GABAA Receptor Agonists Product Portfolio
  138. 4.23.5 CHEPLAPHARM Recent Developments
  139. 4.24 Apotex
  140. 4.24.1 Apotex Company Information
  141. 4.24.2 Apotex Business Overview
  142. 4.24.3 Apotex GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Apotex GABAA Receptor Agonists Product Portfolio
  144. 4.24.5 Apotex Recent Developments
  145. 4.25 Akorn
  146. 4.25.1 Akorn Company Information
  147. 4.25.2 Akorn Business Overview
  148. 4.25.3 Akorn GABAA Receptor Agonists Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Akorn GABAA Receptor Agonists Product Portfolio
  150. 4.25.5 Akorn Recent Developments
5 Global GABAA Receptor Agonists Market Scenario by Region
  1. 5.1 Global GABAA Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global GABAA Receptor Agonists Sales by Region: 2021-2032
  3. 5.2.1 Global GABAA Receptor Agonists Sales by Region: 2021-2026
  4. 5.2.2 Global GABAA Receptor Agonists Sales by Region: 2027-2032
  5. 5.3 Global GABAA Receptor Agonists Revenue by Region: 2021-2032
  6. 5.3.1 Global GABAA Receptor Agonists Revenue by Region: 2021-2026
  7. 5.3.2 Global GABAA Receptor Agonists Revenue by Region: 2027-2032
  8. 5.4 North America GABAA Receptor Agonists Market Facts & Figures by Country
  9. 5.4.1 North America GABAA Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America GABAA Receptor Agonists Sales by Country (2021-2032)
  11. 5.4.3 North America GABAA Receptor Agonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe GABAA Receptor Agonists Market Facts & Figures by Country
  16. 5.5.1 Europe GABAA Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe GABAA Receptor Agonists Sales by Country (2021-2032)
  18. 5.5.3 Europe GABAA Receptor Agonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific GABAA Receptor Agonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific GABAA Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific GABAA Receptor Agonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific GABAA Receptor Agonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America GABAA Receptor Agonists Market Facts & Figures by Country
  41. 5.7.1 South America GABAA Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America GABAA Receptor Agonists Sales by Country (2021-2032)
  43. 5.7.3 South America GABAA Receptor Agonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa GABAA Receptor Agonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa GABAA Receptor Agonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa GABAA Receptor Agonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa GABAA Receptor Agonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global GABAA Receptor Agonists Sales by Type (2021-2032)
  2. 6.1.1 Global GABAA Receptor Agonists Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global GABAA Receptor Agonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global GABAA Receptor Agonists Revenue by Type (2021-2032)
  5. 6.2.1 Global GABAA Receptor Agonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global GABAA Receptor Agonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global GABAA Receptor Agonists Sales by Application (2021-2032)
  2. 7.1.1 Global GABAA Receptor Agonists Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global GABAA Receptor Agonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global GABAA Receptor Agonists Revenue by Application (2021-2032)
  5. 7.2.1 Global GABAA Receptor Agonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global GABAA Receptor Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 GABAA Receptor Agonists Value Chain Analysis
  2. 8.1.1 GABAA Receptor Agonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 GABAA Receptor Agonists Production Mode & Process
  5. 8.2 GABAA Receptor Agonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 GABAA Receptor Agonists Distributors
  8. 8.2.3 GABAA Receptor Agonists Customers
9 Global GABAA Receptor Agonists Analyzing Market Dynamics
  1. 9.1 GABAA Receptor Agonists Industry Trends
  2. 9.2 GABAA Receptor Agonists Industry Drivers
  3. 9.3 GABAA Receptor Agonists Industry Opportunities and Challenges
  4. 9.4 GABAA Receptor Agonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst